secwatch.observer — SEC 8-K summary
======================================

Issuer:     Generation Bio Co. (—)
CIK:        0001733294
Form:       8-K
Filed at:   2025-01-06T23:59:59+00:00
Accession:  0001558370-25-000035
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Generation Bio pivots to ctLNP siRNA for autoimmune diseases; CFO, CSO exit; cuts 20% staff
--------------------------------------------------------------------------------

- New focus on ctLNP-delivered siRNA for T cell-driven autoimmune diseases; first IND expected 2H 2026.
- CFO Matthew Norkunas departs Jan 10; Kevin Conway appointed CFO with $420K salary and 290,960 option grant.
- CSO Matthew Stanton departs; Phillip Samayoa appointed CSO with $510K salary; Stanton to consult through mid-2025.
- Workforce reduced ~20%; severance costs estimated $1-2M; cash runway into 2H 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733294/000155837025000035/0001558370-25-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733294/000155837025000035/gbio-20250106x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer